Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by emerald03on Apr 28, 2023 7:08am
77 Views
Post# 35418629

RE:RE:RE:13 going to hold?

RE:RE:RE:13 going to hold?I would base the  proposed rise   that xould be rapid on discounted cash flow in  the not too distant future fiscal years

The cash flow could go towards the region of 50 to 100 million dollars annual for Sirona 

Add on a large anticipated   initial licensing payment that potentially should be tens of millions of dollars in the face of the high quality results and multiple competing companies,

And then add on takeover speculation ,which  the management may be happy to encourage for the right price ,as they are not getting any younger themselves, just like all of us.
Takeover could be no less than 2 to 3 USD ,and we are at 13 cents right now,and could even happen within 12 months ,once the companies have had time to look at the data .
<< Previous
Bullboard Posts
Next >>